Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on International Tech Times.
Press releases published on April 28, 2025

Biomed Valley Discoveries Announces First Patient Dosed in Phase 1/2 Combination Study of Ulixertinib with Ruxolitinib (Jakafi®) in Patients with Myelofibrosis
-- Dual targeting of JAK 1/2 (ruxolitinib) and ERK 1/2 (ulixertinib) may represent a novel treatment approach for myelofibrosis and possibly other myeloproliferative neoplasms KANSAS CITY, Mo., April 28, 2025 (GLOBE NEWSWIRE) -- Biomed Valley Discoveries ( …

Hudbay’s Eugene Lei wins Globe and Mail’s Report on Business 2025 Best Executive Award
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Hudbay Minerals Inc. (“Hudbay” or the “Company”) (TSX, NYSE: HBM) is pleased to announce that Eugene Lei, Chief Financial Officer at Hudbay, has been recognized as a winner of the Globe and Mail’s Report on …

EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease
Initial real-world data from nearly 40,000 EYLEA HD patients will provide early insights on effectiveness of EYLEA HD in everyday clinical practice New indirect comparisons will evaluate EYLEA HD and faricimab on measures of efficacy, dosing frequency and …

Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting
LONDON and PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced …

AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening
LONDON and PHOENIX, Ariz., April 28, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, and EmeritusDX, a rapidly growing cancer …

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial …

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today …

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first …

Widmer Brothers Brewing Celebrates 40th Anniversary
PORTLAND, Ore., April 28, 2025 (GLOBE NEWSWIRE) -- Widmer Brothers Brewing, the creator of the Original American Hefeweizen and a Tilray Brands, Inc., (NASDAQ: TLRY and TSX: TLRY) craft beer brand, commemorates its 40th anniversary with the launch of the " …

Atana Expands Sales Team, Welcomes New Leaders to Drive Continued Growth
BELLEVUE, Wash., April 28, 2025 (GLOBE NEWSWIRE) -- Seeking to redefine workplace culture and training, Atana today announced that Deena Perro and Brett Seller have joined the company’s growing sales team as demand for its award-winning solutions increases …

Lungpacer to Showcase the Potential of Novel Technologies to Improve Lung, Heart, and Brain Health in Ventilated Patients
EXTON, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- This spring, Lungpacer Medical clinical experts and device innovators will be featured presenters at top industry events. Speakers will demonstrate how novel interventional therapies can free critically ill …

Benevity Appoints Industry’s First Chief Artificial Intelligence Officer
CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- Benevity Inc. today announced the appointment of Ian Goldsmith as Chief Artificial Intelligence (AI) Officer, the first such dedicated role in the corporate social responsibility (CSR) and social impact …

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-estrogen therapy CDK2 MGD delayed resistance to CDK4/6 …

AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer
MILAN, April 28, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the appointment of Mr …

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28, 2025 ( …

Clear Blue Technologies International to provide Corporate Update and Report Fiscal 2024 Financial Results and Host Conference Call on Thursday, May 1st, 2025
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Clear Blue Technologies International Inc. (TSXV: CBLU) the Smart Off-Grid™ Company, today announces that it will provide a corporate update and also report financial results for its fiscal 2024 on Wednesday, …

ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA’s Uniquely Efficient Internal R…

Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified 5 of 7 best overall response evaluable patients …

Auron Presents Preclinical Data Highlighting the Activity of AUTX-703 in Prostate Cancer at 2025 AACR Annual Meeting
NEWTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced preclinical data in prostate …

Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
ROCKVILLE, Md. and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs …